ArticleJournal of translational medicine2012
Effects of adjuvants on IgG subclasses elicited by virus-like particles.
Article in Journal of translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 82 citations in OpenAlex.
- From Mycosynthesis to Immunomodulation: Exploring the Safety, Adjuvant Potential and Microbiota Impact of Biogenic Silver Nanoparticles.Microbial biotechnology · 2026Article
- BCG enables protection against malaria through adjuvanting an adenovirus-vectored vaccine.NPJ vaccines · 2026Article
- Age-associated B cells, key players in autoimmune pathogenesis.Immunity & ageing : I & A · 2026Review
- Antibody response induced by structural proteins fromFrontiers in microbiology · 2026Article
- Review
- Review
- Immunogenicity and Safety Profile of Two Adjuvanted-PD-L1-Based Vaccine Candidates in Mice, Rats, Rabbits, and Cynomolgus Monkeys.Vaccines · 2025Article
- Astragalus Polysaccharide Nanoemulsion: A Promising Adjuvant for Foot-And-Mouth Disease Virus-Like Particle Vaccines.Transboundary and emerging diseases · 2025Article
- Article
- Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.PLoS pathogens · 2024Article
- Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in QIV vaccinated mice.bioRxiv : the preprint server for biology · 2024Article
- Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in quadrivalent influenza vaccine vaccinated mice.Frontiers in immunology · 2024Article
- Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.Cell reports. Medicine · 2023Article
- Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants.Drug delivery and translational research · 2023Article
- Fluorine-Functionalized Polyphosphazene Immunoadjuvant: Synthesis, Solution Behavior and In Vivo Potency.Molecules (Basel, Switzerland) · 2023Article
- Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19.NPJ vaccines · 2023Article
- Protein Nanoparticle-Mediated Delivery of Recombinant Influenza Hemagglutinin Enhances Immunogenicity and Breadth of the Antibody Response.ACS infectious diseases · 2023Article
- Article
- Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice.Frontiers in immunology · 2023Article
- Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice.Science translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVirus-Like Particles (VLPs) represent an efficient strategy to present and deliver conformational antigens to the immune system, inducing both arms of the adaptive immune response. Moreover, their particulate structure surrounded by cell membrane provides an adjuvanted effect to VLP-based immunizations. In the present study, the elicitation of different patterns of IgG subclasses by VLPs, administered in CpG ODN1826 or poly(I:C) adjuvants, has been evaluated in an animal model.
resultsAdjuvanted VLPs elicited a higher titer of total specific IgG compared to VLPs alone. Furthermore, while VLPs alone induced a balanced TH2 pattern, VLPs formulated with either adjuvant elicited a TH1-biased IgG subclasses (IgG2a and IgG3), with poly(I:C) more potent than CpG ODN1826.
conclusionsThe results confirmed that adjuvants efficiently improve antigen immunogenicity and represent a suitable strategy to skew the adaptive immune response toward the differentiation of the desired T helper subset, also using VLPs as antigen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.